Assoc. Prof. Dr. Kubilay Karaboyun

Образование и специализация

2008–2014 — Медицинский факультет Cerrahpaşa — медицинское образование

2015–2019 — Учебно-исследовательские больницы Kartal Dr. Lütfi Kırdar и Bakırköy Dr. Sadi Konuk — специализация по внутренним болезням

2020–2023 — Университет Tekirdağ Namık Kemal — специализация по медицинской онкологии

2024 — Учебно-исследовательская больница Ağrı — звание доцента

Профессиональный опыт

2014 — Государственная больница Suluova — врач общей практики

2019–2020 — Государственная больница Akçakale — специалист по внутренним болезням

2024–2025 — Учебно-исследовательская больница Ağrı — медицинский онколог

2025 — Учебно-исследовательская больница Bağcılar — медицинский онколог

Medical Park Gaziosmanpaşa Университета İstinye

Клинические интересы

Рак молочной железы

Рак лёгкого

Рак предстательной железы

Опухоли желудочно-кишечного тракта

Урогенитальные опухоли

Гинекологические опухоли

Таргетная и персонализированная терапия

Курсы и сертификаты

2023 — Сертификат квалификационного экзамена Европейского общества медицинской онкологии (ESMO)

2024 — Стамбульский университет — сертификат подготовки преподавателей

Исследования и публикации

Ozkan Alan; Tugba Akın Telli; Sinem Akbas; Selver Isik; Eyyüb Çavdar; Kubilay Karaboyun; Aysegül Merc Cetinkaya; Ferhat Ekinci; Atike Pınar Erdoğan; Mahmut Büyükşimsek et al. Prognostic Role of Inflammatory and Nutritional Indices in NSCLC Patients Treated with Immune Checkpoint Inhibitors: Retrospective, Multicenter, Turkish Oncology Group Study of Overall and Elderly Populations.

E Cavdar, K Karaboyun, Y Iriagac Nanotechnology in oncology: a mini review

O Avci, E Çavdar, Y İriağaç, K Karaboyun et al. Soluble B7H3 level in breast cancer and its relationship with clinicopathological variables and T-cell infiltration

ES Şeber, Y İriagac, E Çavdar, K Karaboyun et al.logarithmic model for hormone receptor-positive and breast cancer patients treated with neoadjuvant chemotherapy.

E Cavdar, K Karaboyun, Y Iriagac, OF Elcicek et al. Prognostic Value of Estrogen Receptor Co-activator AIB1 in Metastatic Breast Cancer Patients Treated with a Combination of Ribociclib and Letrozole

K Karaboyun, E Cavdar, Y Iriagac, SY Tacar et al. Fertility Desire and Protection Practices Among Turkish Young Breast Cancer Patients Treated with Chemotherapy.

E Cavdar, K Karaboyun, Y Iriagac, A Celikkol et al. Creatine Kinase (CK)-MB and CK-MB-to-Total-CK Ratio: A Novel Predictive Marker for Pathologic Complete Response in Breast Cancer Treated with Neoadjuvant Chemotherapy

K Karaboyun. Evaluating inflammatory markers as predictive tools for advanced non-small cell lung cancer receiving nivolumab

Y İriağaç, K Karaboyun, TİK ÖZÇAĞLAYAN et al. The diagnostic contribution of magnetic resonance imaging in the detection of axillary metastasis after neoadjuvant chemotherapy.

Y Iriagac, E Cavdar, K Karaboyun, SY Tacar et al. A new predictive marker for predicting response after neoadjuvant chemotherapy in hormone receptor positive/HER2-negative patients: a logarithmic model

Cengiz Karacin, Berna Oksuzoglu, Ayşe Demirci,…, S Karakaya, E Kut, F Teker, BÇ Demirel, K Karaboyunet al. Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy

E Cavdar, K Karaboyun, K Kara. Comprehensive analysis of the prognostic role of laboratory indices in advanced lung cancer patients

E Cavdar, Y Iriagac, K Karaboyun, O Avci. Prospective comparison of the value of CARG, G8, and VES-13 toxicity tools in predicting chemotherapy-related toxicity in older Turkish patients with cancer

O Avcı, Y İriağaç, E Çavdar, K Karaboyun. PROPSEA, safety evaluation of palbociclib and ribociclib in older patients with breast cancer: A prospective real-world TOG study

Y İriağaç, E Çavdar, K Karaboyun, O Avci. The influence of visual objects and music on anxiety levels of breast cancer patients scheduled to experience chemotherapy for the first time: a prospective randomized clinical study

K Karaboyun, Y İriağaç, E Çavdar et al. Comparison of three equations for estimating glomerular filtration rate as predictors of cisplatin-related acute kidney injury in lung cancer patients with normal renal function

E Cavdar, Y Iriagac, K Karaboyun et al. Prognostic Role of Lymphovascular Invasion and Perineural Invasion in Breast Cancer Treated with Neoadjuvant Chemotherapy.

K Karaboyun, E Cavdar, Y Irıagac, A Celebı et al. Tamoxifen or aromatase inhibitors: which one is the culprit of urinary incontinence in premenopausal breast cancer patients receiving adjuvant hormone therapy?

I Yakup, C Eyyup, K Kubilay, A Okan et al. Immunogenicity and safety of the CoronaVac vaccine in patients undergoing treatment for breast and lung cancer.

Seber E. S., Iriagac Y., Cavdar E., Karaboyun K., Avci O., Yolcu A et al. Efficacy of neoadjuvant chemotherapy in lobular and rare subtypes of breast cancer

E Cavdar, K Karaboyun, Y Iriagac et al. Use of Complementary Therapy in Lung Cancer Patients Treated with Chemotherapy and its Effect on Survival: A Cross-sectional Study

K Karaboyun, S Girgin, M Yılmaz et al. Mortalidad a los 90 días y al año y resultados renales de pacientes que iniciaron tratamiento con hemodiálisis por primera vez

K Karaboyun, ES Şeber. The prognostic role of neutrophil/lymphocyte ratio and monocyte/lymphocyte ratio in advanced stage gastric cancer patients receiving chemotherapy: a single center experience

E Cavdar, Y Iriagac, K Karaboyun, O Avci, ES Seber. Understanding breast cancer from the patients' perspective

Y Iriagac, E Cavdar, K Karaboyun et al. Decrease in estimated glomerular filtration rates in non-small cell lung cancer patients treated with crizotinib

E ÇAVDAR, K KARABOYUN et al. Survival Impact of Adjuvant Chemoradiotherapy in Resected Pancreatic Cancer

K Karaboyun, E Çavdar, Y İriağaç et al. The Role of Interleukin-20 in Paclitaxel-Associated Peripheral Neuropathy in Non-Metastatic Breast Cancer Patients Receiving Chemotherapy

K Karaboyun, Y Iriagac, E Cavdar, O Avci, ES Seber. A New Mortality Prediction Model in Advanced Stage Cancer Patients Requiring Hospitalisation while Receiving Active Systemic Therapy

E Cavdar, K Karaboyun, Y Iriagac, O Avciet al. Efficacy and safety of trastuzumab emtansine treatment in patients with metastatic HER-2 positive breast cancer: a single center study

K Karaboyun, M Öznur, A Yolcu, Y İriağaç et al. Investigation of the Effect of Low-positive HER-2 on Neoadjuvant Chemotherapy Response in Hormone-positive Breast Cancer Patients

Halil İbrahim Ellez ,…, Ertuğrul Bayram, Kubilay Karaboyun et al. Denosumab administration in breast, prostate and lung cancer with chronic kidney disease–a retrospective multicenter Turkish Oncology Group (TOG) study

K Karaboyun, A Yolcu. Prognostic factors influencing regorafenib treatment outcomes in metastatic colorectal cancer

Y İRİAĞAÇ, K KARABOYUN et al. Effects of COVID-19 Pandemic on Diagnosis-treatment Process in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy

Главы в книгах

T YETİŞYİĞİT, K KARABOYUN. Lenfomagenez. Turkiye Klinikleri Medical Oncology

K KARABOYUN, NS DEMİRCİ - Baş-Boyun Kanserlerinde İmmünoterapi.2022 - turkiyeklinikleri.com

Kkaraboyun, Asakin. Geleneksel Çin Tıbbı. KANSER HASTALARININ BAŞVURDUĞU GELENEKSEL VE TAMAMLAYICI TEDAVILER.